TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Snehal Patel
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences reported an approximately 80% reduction in breast cancer recurrence rates in the non-HLA-A*02 arm of its FLAMINGO-01 Phase III clinical trial, using two estimation methods for its GLSI-100 immunotherapy treatment.

Insights
COLAR   positive

Successfully securing a merger with an innovative technology company in the satellite and quantum security space


GLSI   positive

Reported promising preliminary results showing significant potential reduction in breast cancer recurrence rates, with early data trending positively and suggesting potential breakthrough in cancer treatment